Table 2 Distribution of the studied patients according to baseline data
From: Electrolyte profile in COVID-19 patients: insights into outcomes
N = 600 | % | |
|---|---|---|
Gender | ||
Male | 334 | 55.7% |
Female | 266 | 44.3% |
Age; mean ± SD | 51.33 ± 16.5 | 21–93 |
Smoking | 113 | 18.83% |
Diabetes | 175 | 29.16% |
Hypertension | 204 | 34% |
Hyperlipidemia | 159 | 26.5% |
Ischemic heart disease | 86 | 14.33% |
Chronic lung disease | 107 | 17.83% |
Drug: | ||
Insulin | 59 | 9.83% |
Oral hypoglycemic drugs | 105 | 17.5% |
Bronchodilators | 89 | 14.83% |
Steroid | 85 | 14.16% |
Antiplatelet | 237 | 39.5% |
Beta-blockers | 99 | 16.5% |
Mechanical ventilation: | 265 | 44.16% |
Non-invasive ventilation | 261 | 43.5% |
Invasive ventilation | 185 | 30.83% |
Non-invasive ventilator days: median (range) | 16 (1–33) | |
Invasive ventilator days: median (range) | 6 (1–17) | |
Length of ICU stay (days): median (range( | 8 (1–70) | |
Outcome: death | 184 | 30.66% |